Primary tabs
Revisions allow you to track differences between multiple versions of your content, and revert back to older versions.
Revision | Operations | |
---|---|---|
07-27-21 by [email protected] | current revision | |
07-26-21 by conan.macdougal... | ||
08-12-20 by conan.macdougal... | ||
08-12-20 by conan.macdougal... | ||
08-12-20 by conan.macdougal... | ||
08-12-20 by conan.macdougal... | ||
08-12-20 by conan.macdougal... | ||
08-12-20 by conan.macdougal... | ||
07-10-20 by [email protected] | ||
04-22-20 by ucsf_admin | ||
04-22-20 by ucsf_admin |
Dosing: Adult Antimicrobial Dosing, Non-dialysis
Indication | Dosing | Notes |
---|---|---|
Mycobacterial infections | 600 mg IV/PO q24h |
No renal dose adjustment |
Prosthetic device infections | 300 mg IV/PO q12h | |
Endocarditis | 300 mg IV/PO q8h |
Dosing: Antimicrobial Dosing in Intermittent & Continuous Hemodialysis
Indication | Dosing | Notes |
---|---|---|
Mycobacterial infections | 600 mg IV/PO q24h |
No adjustment in hemodialysis |
Prosthetic device infections | 300 mg IV/PO q12h | |
Endocarditis | 300 mg IV/PO q8h |
Dialysis Notes
Intermittent HD assumes high-flux hemodialysis. CRRT assumes CVVHD with ultrafiltration rate 2L/h and residual native GFR < 10 mL/min. For detailed view of dialysis dosing and evidence, see Dosing in Hemodialysis document.
Review medications for potential drug interactions.